(2S,3S)-1-amino-2,3,4-butanetriol | 168113-19-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (2S,3S)-1-amino-2,3,4-butanetriol
• 英文别名: (2S,3S)-1-aminobutane-2,3,4-triol；(S,S)-4-amino-1,2,3-butanetriol；(2S,3S)-4-aminobutane-1,2,3-triol
• CAS: 168113-19-7
• 化学式: C₄H₁₁NO₃
• 分子量: 121.136
• InChiKey: WIFPJDJJFUSIFP-IMJSIDKUSA-N

物化性质

• 沸点：
  357.0±42.0 °C(Predicted)
• 密度：
  1.323±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.5
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  86.7
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2R,3S,5R)-5-[2-氟-6-(2-三甲基硅烷基乙氧基)嘌呤-9-基]-2-(羟基甲基)四氢呋喃-3-醇 、 (2S,3S)-1-amino-2,3,4-butanetriol 在 N,N-二异丙基乙胺 、 溶剂黄146 作用下， 以 二甲基亚砜 、 水 为溶剂， 反应 74.0h， 生成 (2S,3S)-2'-deoxy-N²-(2,3,4-trihydroxybut-1-yl)guanosine
  参考文献：
  名称：

  Synthesis and Characterization of Nucleosides and Oligonucleotides Bearing Adducts of Butadiene Epoxides on Adenine N⁶ and Guanine N²

  摘要：

  Butadiene is a major industrial chemical whose genotoxic effects are attributed to the reaction of its oxidized metabolites, butadiene monoepoxide (BDO) and butadiene diepoxide (BDO2), with DNA, Nucleosides and oligonucleotides containing regio- and stereochemically specific adducts of BDO and the BDO2-related compound, butene 3,4-diol 1,2-epoxide (BDE), on guanine [(2R)- and (2S)-N-2-(1-hydroxy-3-buten-2-yl) and (2R,3R)- and (2S,3S)-N-2-(2,3,4-trihydroxybutl-yl), respectively] and on adenine [(2R)- and (2S)-N-6-(1-hydroxy-3-buten-2-yl) and (2R,3R)and (2S,3S)-N-6-(2,3,4-trihydroxybut-1-yl), respectively] have been prepared by nonbiomimetic routes, For guanine adducts, 2-fluoro-O-6-(trimethylsilylethyl)-2 ' -deox was treated with (2R)- and (2S)-2-amino-3-buten-1-ol to give the BDO adducts and with (2R,3R)- and (25,35)1-amino-2,3,4-butanetriol to produce the BDE adducts; the adducted oligonucleotides were prepared from 11-mer oligonucleotides containing the halopurine. Adenine adducts were prepared in a similar fashion using 6-chloropurine 2 ' -deoxyriboside as the reactive purine component.

  DOI：

  10.1021/tx000241k
• 作为产物：
  描述：

  (2S,3R)-3,4-isopropylidene-1-amino-2,3,4-butanetriol 在 盐酸 作用下， 以 四氢呋喃 为溶剂， 反应 20.0h， 以90%的产率得到(2S,3S)-1-amino-2,3,4-butanetriol
  参考文献：
  名称：

  Synthesis and Characterization of Nucleosides and Oligonucleotides Bearing Adducts of Butadiene Epoxides on Adenine N⁶ and Guanine N²

  摘要：

  Butadiene is a major industrial chemical whose genotoxic effects are attributed to the reaction of its oxidized metabolites, butadiene monoepoxide (BDO) and butadiene diepoxide (BDO2), with DNA, Nucleosides and oligonucleotides containing regio- and stereochemically specific adducts of BDO and the BDO2-related compound, butene 3,4-diol 1,2-epoxide (BDE), on guanine [(2R)- and (2S)-N-2-(1-hydroxy-3-buten-2-yl) and (2R,3R)- and (2S,3S)-N-2-(2,3,4-trihydroxybutl-yl), respectively] and on adenine [(2R)- and (2S)-N-6-(1-hydroxy-3-buten-2-yl) and (2R,3R)and (2S,3S)-N-6-(2,3,4-trihydroxybut-1-yl), respectively] have been prepared by nonbiomimetic routes, For guanine adducts, 2-fluoro-O-6-(trimethylsilylethyl)-2 ' -deox was treated with (2R)- and (2S)-2-amino-3-buten-1-ol to give the BDO adducts and with (2R,3R)- and (25,35)1-amino-2,3,4-butanetriol to produce the BDE adducts; the adducted oligonucleotides were prepared from 11-mer oligonucleotides containing the halopurine. Adenine adducts were prepared in a similar fashion using 6-chloropurine 2 ' -deoxyriboside as the reactive purine component.

  DOI：

  10.1021/tx000241k

文献信息

• Kinase inhibitors
  申请人：——

  公开号：US20040019210A1

  公开（公告）日：2004-01-29

  This invention provides phenyl-substituted pyrimidopyrimidines, dihydropyrimido-pyrimidines, pyridopyrimidines, naphthyridines, and pyridopyrazines of the general formula: 1 that inhibit cyclin-dependent kinase and tyrosine kinase enzymes, methods and intermediate compounds for their synthesis, as well as pharmaceutical compositions and methods for their use in treating, inhibiting or preventing maladies associated with cell proliferative disorders, including angiogenesis, atherosclerosis, restenosis, and cancer.

  本发明提供了通式1中的苯基取代的嘧啶嘧啶、二氢嘧啶嘧啶、吡啶嘧啶、萘嘧啶和吡啶吡嗪，这些化合物能够抑制细胞周期依赖性激酶和酪氨酸激酶酶活性，以及它们的合成方法和中间体化合物，还包括制备药物组合物和治疗、抑制或预防与细胞增殖紊乱相关的疾病，包括血管生成、动脉粥样硬化、再狭窄和癌症的方法。
• Benzamide derivative
  申请人：Koyano Hiroshi

  公开号：US20070123493A1

  公开（公告）日：2007-05-31

  To provide compounds which have high angiogenesis inhibiting activity, and are useful as agents for effective treatment and prevention of diseases involving pathologic angiogenesis, for example, cancer and cancer metastasis, methods for producing the compounds, intermediate compounds useful for their production, and pharmaceutical compositions containing these compounds. The present invention provides compounds of formula (II), or prodrugs thereof, or pharmaceutically acceptable salts of the compounds or the prodrugs, and pharmaceuticals, and pharmaceutical compositions containing these compounds: where A 1 is C—X 1 or N; Q 1 is —A 2 ═A 3 —, or a heteroatom selected from —O—, —S—, and —N(R 10 )—; Q 2 is —A 4 ═A 5 —, or a heteroatom selected from —O—, —S—, and —N(R 10 )—; provided that Q 1 and Q 2 are not heteroatoms at the same time; A 2 is C—X 2 or N, A 3 is C—X 3 or N, A 4 is C—X 4 or N, and A 5 is C—X 5 or N; Y is C 1-6 alkyl, C 3-9 cycloalkyl, C 2-7 alkenyl, C 2-7 alkynyl, C 1-6 alkoxy, C 2-7 alkenyloxy, C 2-7 alkynyloxy, or C 1-6 alkylthio; Z is a hydrogen atom, hydroxy, C 1-6 alkyl, C 3-9 cycloalkyl, or —NR 1 R 2 ; and L is selected from the formula:

  提供具有高抑制血管生成活性的化合物，可用作治疗和预防涉及病理性血管生成的疾病的药物，例如癌症和癌症转移，以及生产这些化合物的方法，用于它们的生产的中间体化合物，以及含有这些化合物的药物组合物。本发明提供以下化合物的配方（II），或其前药，或该化合物或前药的药学上可接受的盐，以及含有这些化合物的药物和药物组合物：其中A1为C-X1或N; Q1为-A2═A3-，或从-O-，-S-和-N（R10）中选择的杂原子; Q2为-A4═A5-，或从-O-，-S-和-N（R10）中选择的杂原子; 前提是Q1和Q2不同时为杂原子; A2为C-X2或N，A3为C-X3或N，A4为C-X4或N，A5为C-X5或N; Y为C1-6烷基，C3-9环烷基，C2-7烯基，C2-7炔基，C1-6烷氧基，C2-7烯氧基，C2-7炔氧基或C1-6烷硫基; Z为氢原子，羟基，C1-6烷基，C3-9环烷基或-NR1R2; L从以下公式中选择：
• BENZAMIDE DERIVATIVE
  申请人：KOYANO Hiroshi

  公开号：US20100179326A1

  公开（公告）日：2010-07-15

  Compounds having high angiogenesis inhibiting activity useful as agents for effective treatment and prevention of diseases involving pathologic angiogenesis, e.g. cancer and cancer metastasis, are of formula (II), where A 1 is C—X 1 or N; Q 1 is -A 2 =A 3 -, or a heteroatom selected from —O—, —S—, and —N(R 10 )—; Q 2 is -A 4 =A 5 -, or a heteroatom selected from —O—, —S—, and —N(R 10 )—; provided that Q 1 and Q 2 are not heteroatoms at the same time; A 2 is C—X 2 or N, A 3 is C—X 3 or N, A 4 is C—X 4 or N, and A 5 is C—X 5 or N; Y is C 2-6 alkyl, C 3-9 cycloalkyl, C 2-7 alkenyl, C 2-7 alkynyl, C 2-6 alkoxy, C 2-7 alkenyloxy, C 2-7 alkynyloxy, or C 1-6 alkylthio; Z is a hydrogen atom, hydroxy, C 1-6 alkyl, C 3-9 cycloalkyl, or —NR 1 R 2 ; and L is selected from the formula:

  具有高抑制血管新生活性的化合物，可用作治疗和预防涉及病理性血管新生的疾病的有效药物，例如癌症和癌症转移，其化学式为（II），其中A1为C-X1或N；Q1为-A2=A3-，或从-O-，-S-和-N（R10）中选择的杂原子；Q2为-A4=A5-，或从-O-，-S-和-N（R10）中选择的杂原子；前提是Q1和Q2不同时为杂原子；A2为C-X2或N，A3为C-X3或N，A4为C-X4或N，A5为C-X5或N；Y为C2-6烷基，C3-9环烷基，C2-7烯基，C2-7炔基，C2-6烷氧基，C2-7烯氧基，C2-7炔氧基或C1-6烷基硫；Z为氢原子，羟基，C1-6烷基，C3-9环烷基或-NR1R2；L从以下公式中选择：
• Synthesis and Characterization of Nucleosides and Oligonucleotides Bearing Adducts of Butadiene Epoxides on Adenine N⁶ and Guanine N²
  作者：Lubomir V. Nechev、Mingzhu Zhang、Dimitrios Tsarouhtsis、Pamela J. Tamura、Amanda S. Wilkinson、Constance M. Harris、Thomas M. Harris

  DOI：10.1021/tx000241k

  日期：2001.4.1

  Butadiene is a major industrial chemical whose genotoxic effects are attributed to the reaction of its oxidized metabolites, butadiene monoepoxide (BDO) and butadiene diepoxide (BDO2), with DNA, Nucleosides and oligonucleotides containing regio- and stereochemically specific adducts of BDO and the BDO2-related compound, butene 3,4-diol 1,2-epoxide (BDE), on guanine [(2R)- and (2S)-N-2-(1-hydroxy-3-buten-2-yl) and (2R,3R)- and (2S,3S)-N-2-(2,3,4-trihydroxybutl-yl), respectively] and on adenine [(2R)- and (2S)-N-6-(1-hydroxy-3-buten-2-yl) and (2R,3R)and (2S,3S)-N-6-(2,3,4-trihydroxybut-1-yl), respectively] have been prepared by nonbiomimetic routes, For guanine adducts, 2-fluoro-O-6-(trimethylsilylethyl)-2 ' -deox was treated with (2R)- and (2S)-2-amino-3-buten-1-ol to give the BDO adducts and with (2R,3R)- and (25,35)1-amino-2,3,4-butanetriol to produce the BDE adducts; the adducted oligonucleotides were prepared from 11-mer oligonucleotides containing the halopurine. Adenine adducts were prepared in a similar fashion using 6-chloropurine 2 ' -deoxyriboside as the reactive purine component.